Growth Differentiation Factor 15 Predicts Chronic Liver Disease Severity

Area of Science:

• Hepatology
• Biomarker Discovery
• Clinical Diagnostics

Background:

• Growth differentiation factor 15 (GDF-15) is a transforming growth factor-β superfamily member.
• GDF-15 is emerging as a significant biomarker across various disease states.
• Its role in predicting liver fibrosis and severity in chronic liver disease requires investigation.

Purpose of the Study:

• To evaluate the clinical performance of GDF-15.
• To determine GDF-15's utility in predicting liver fibrosis.
• To assess GDF-15's accuracy in staging chronic liver disease severity.

Main Methods:

• Serum GDF-15 levels were measured using enzyme immunoassay.
• 145 patients with chronic liver disease (hepatitis, compensated/decompensated cirrhosis) and 101 healthy controls were analyzed.
• Receiver operating characteristic (ROC) curves were used to determine diagnostic accuracy.

Main Results:

• Serum GDF-15 levels were significantly higher in decompensated cirrhosis (3,483 ng/L) compared to compensated cirrhosis (1,861 ng/L) and chronic hepatitis (1,232 ng/L).
• GDF-15 demonstrated high diagnostic accuracy for compensated cirrhosis (AUC=0.886) and decompensated cirrhosis (AUC=0.984).
• Specific thresholds for GDF-15 were identified for predicting each stage of liver disease.

Conclusions:

• This study is the first to establish the utility of GDF-15 in chronic liver disease.
• GDF-15 serves as a valuable biomarker for predicting liver fibrosis and disease severity.
• GDF-15 shows potential for non-invasive assessment of liver disease progression.